BCC carcinogenesis is ligand-independent because the HH pathway is constitutively activated by changes in its components, involving gain-of-function (GOF) mutations in the SMO gene and loss-of-function (LOF) mutations in the PTCH1 or SUFU genes [1]. The gene discussed is PTCH1; the disease is skin basal cell carcinoma.